Multiple Sclerosis and Related Disorders

Article	Citations
Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity	80
The nutritional risk in patients with neuromyelitis optica spectrum disorder	65
CNS resilience in the progression of MS	64
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination	57
Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022	56
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis	53
Chlamydia pneumonia infection and risk of multiple sclerosis: A meta-analysis	52
Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study	51
The effects of balance training on cognitive function in persons with multiple sclerosis: A systematic review and meta-analysis	48
Characteristics and predictors of sexual dysfunction in men with multiple sclerosis	47
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study	46
The clinical and radiological features and prevalence of Neuro-Behçet's Disease: A retrospective cohort multicenter study in Saudi Arabia	44
Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder	43
OCT-Angiography in AQP4-positive NMOSD: finding subclinical disease using a new tool	42
Progressive post infectious neurological syndromes with a poor outcome: Long term follow-up and neurofilament light chain quantification	40
Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients	40
Clinical outcomes of partial sensory root rhizotomy on patients with recurrence of multiple sclerosing trigeminal neuralgia after percutaneous balloon compression	39
Spatio-Temporal Gait Parameters to Distinguish Multiple Sclerosis Disability during Dual- Task Walk	39
Utilizing the ISway to Identify and Compare Balance Domain Deficits in People with Multiple Sclerosis	38
Inform Interferon Beta Exposure in the 2nd and 3rd Trimester of Pregnancy: A Register-Based Drug Utilisation Study in Finland and Sweden	37
The Effect of Seasonal Variation on Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis in Saudi Arabia	37
Challenges of MS Patients for Receiving Health Care Services	37
Peripheral nerve vulnerability as risk factor for multiple sclerosis: Possible insights from Neurofibromatosis type 2 (NF2)	36
Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany	36
Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease	36

Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study	35
Patient reported outcomes in a secondary progressive MS cohort related to cognition, MRI and physical outcomes	34
Effects of flexible scheduling and virtual visits on burnout for clinicians: 1- year follow-up	33
How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?	33
Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis	33
Symptomatic trigeminal autonomic cephalalgias in neuromyelitis optica spectrum disorders	33
Infrequent patterns in cerebrospinal fluid isofocusing test: Clinical significance and contribution of IgG index and Reiber diagram to their interpretation	32
The presence of SARS-CoV2 antibodies in MS patients	32
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects	32
Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients	32
Dosing schedules for Ofatumumab in multiple sclerosis: Overegging the pudding	31
An epidemiological analysis of multiple sclerosis patients hospitalized in the United States	31
Nordic clues for uncovering the aetiology of Multiple Sclerosis	31
Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis	30
Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders	30
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis	29
Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report	29
Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy	28
Protective effects of Herbal Compound (IM253) on the inflammatory responses and oxidative stress in a mouse model of multiple sclerosis	27
MOG antibody prevalence in adult optic neuritis and clinical predictive factors for diagnosis: A Chinese cohort study	27
Body size perceptions & diet modification in youth with multiple sclerosis	27
A comparison of the measurement properties of the PROMIS Fatigue (MS) 8a against legacy fatigue questionnaires	26
Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?	26
Fatigue in multiple sclerosis is associated with socioeconomic factors	26
Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis	26
Fatigue in multiple sclerosis: A UK MS-register based study	26
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis	26
Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic	25
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia	25
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology	25
Preventing multiple sclerosis misdiagnosis using the “central vein sign”: A real-world study	25
Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis	25
Cognitive impairment, fatigue and depression in multiple sclerosis: Is there a difference between benign and non-benign MS?	25
Longitudinal analysis of disability outcomes among young people with MS	25
Real World Experience for Cladribine Tablets in Management of Relapsing Multiple Sclerosis in UAE: Cohort Study from Rashid Hospital -Dubai	24
Economic Analysis for Introduction of Cladribine Tablets as a Treatment for Relapsing Multiple Sclerosis Patients with High Disease Activity in Kuwait	24
Radiomics models based on cortical damages for identification of multiple sclerosis with cognitive impairment	24
Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis	24
Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression	24
Mechanisms of myelin repair, MRI techniques and therapeutic opportunities in multiple sclerosis	24
Concomitant autoimmunity and risk of multiple sclerosis disability worsening	23
The Indian multiple sclerosis and allied demyelinating disorders registry and research network (IMSRN): Inception to reality	23
The impact of bladder problems on well-being in multiple sclerosis – A cross-sectional study	23
Exploring suicidal ideation prevalence in multiple sclerosis patients during the COVID-19 pandemic: A study on the relationship between drug use and suicidal ideation	23
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021	23
Suicidal ideation in people with multiple sclerosis and its association with coping self-efficacy	23
The telephone-based application of the modified fatigue impact scale in individuals with multiple sclerosis: An investigation of measurement properties	23
Clinical outcome analysis of patients with multiple sclerosis – Analysis from the UK Medical Cannabis Registry	22
Comparison of the effects of mechanical hippotherapy and Cawthorne-Cooksey exercises in patients with multiple sclerosis: Randomized trial	22
Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study	22

Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis	22
Why I created the Rachel Horne Prize for Women's Research in Multiple Sclerosis	22
Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients	22
Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis	21
COVID-19 vaccines and multiple sclerosis disease-modifying therapies	21
Iron in multiple sclerosis – Neuropathology, immunology, and real-world considerations	21
Multiple sclerosis is associated with adverse outcomes following hip and knee arthroplasty: A systematic review and meta-analysis of observational studies	21
Parkinsonism in multiple sclerosis patients: A prospective observational study	21
Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis	21
Clinical analysis of adult MOG antibody-associated cortical encephalitis	21
A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: A single-center tertiary care cohort	21
Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective	21
Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.	21
Milk and multiple sclerosis: A possible link?	21
Use of natalizumab in persons with multiple sclerosis: 2022 update	21
Psychological symptoms in Multiple Sclerosis and the role of marital status: results from a retrospective single-center study	21
Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America	20
A multicenter study of radiologically isolated syndrome in children and adolescents: Can we predict the course?	20
The relationship between bladder functions, pelvic floor muscle strength, fall, and fatigue in multiple sclerosis	20
Do we still need OCBs in MS diagnosis and how many?	20
The effect of a mobile education application (MobilMS) developed for multiple sclerosis patients in Turkey on symptom management and quality of life: A randomized controlled study	20
Demographic features, behavioral measures, and clinical factors as predictors of cognitive function in patients with multiple sclerosis	20
Effects of backward walking training on balance, gait, and functional mobility in people with multiple sclerosis: A randomized controlled study	20
Real world study of ocrelizumab in multiple sclerosis: Kuwait experience	20
Independent and reproducible hippocampal radiomics biomarkers for multisite multiple sclerosis and neuromyelitis optica spectrum disorders	20
Prolonged visual evoked potential latency predicts longitudinal worsening of fatigue in people with multiple sclerosis	20
Characterizing causal relationships of visceral fat and body shape on multiple sclerosis risk	20
Post-vaccination SARS-Cov-2 T-cell receptor repertoires and multiple sclerosis and related disorders: Correspondence	20
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina	20
A mixture model for differentiating longitudinal courses of multiple sclerosis	20
Multiple Sclerosis During Pregnancy: Data from the MS Clinic in Benghazi Medical Center	19
The dilated cortical veins found in multiple sclerosis can explain the reduction in glymphatic flow	19
Primary Antiphospholipid Antibody Syndrome Mimicking a Progressive MS: Case Report	19
The Relationship Between Smoking and Multiple Sclerosis Severity in Saudi Arabia	19
Initial validation of the university of Alabama Birmingham study of aging life-space assessment in older adults with multiple sclerosis	19
Leber Hereditary Optic Neuropathy Presenting as Bilateral Visual Loss and White Matter Disease	19
Menopausal symptoms and hormone therapy in women with multiple sclerosis: A baseline-controlled study	19
Clinical, Evolutionary and Etiological Particularities of Inflammatory Optic Neuropathies: An Algerian Population	19
Vitamin D-Related Parameters and Th17 Pathway in Multiple Sclerosis: A Serological, Transcriptomic and Functional Study	19
Sexual Dysfunctions and Self-Esteem in Multiple Sclerosis: A Tunisian Study	18
Reliability and Validity of the Arabic Version of Brief International Cognitive Assessment for Multiple Sclerosis in Egyptian Pediatric Multiple Sclerosis Patient	18
Real World Experience for Clad T in the Management of Relapsing Multiple Sclerosis in the United Arab Emirates	18
Health related quality of life and perceived social support in French and Lebanese MS patients: A comparative study	18
Sexual Dysfunction during Multiple Sclerosis	18
Atypical Cerebral MRI Imaging Associated Related to NMOSD	18
Neuromyelitis Optica Spectrum Disorders Mimicking Wernicke's Encephalopathy: Difficult Differential Diagnosis	18
Effectiveness & Safety Profile of Fingolimod in Treating Omani Patients with Multiple Sclerosis, Single Tertiary Center Experience	18
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine	18
Effects of crocin on inflammatory biomarkers and mental health status in patients with multiple sclerosis: A randomized, double-blinded clinical trial	18
Identification of potential key genes and immune infiltration in Multiple sclerosis	18
Real-Life Study with Cladribine: Kuwait Experience	18
Expert Opinion on Long-Term Use of Cladribine Tablets for Multiple Sclerosis: Systematic Literature Review of Real-World Evidence	18
What is the role of diet for multiple sclerosis? Why epidemiological studies don't give the full answer	18
"Dry oral and ocular manifestations and autoantibodies characteristic of primary Sjögren's syndrome in multiple sclerosis"	17
Neutrophil to lymphocyte ratio may be a useful marker in distinguishing MOGAD and MS and platelet to lymphocyte ratio associated with MOGAD activity	17
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy	17
Oral disease modifying therapies – A game changer for treatment decision in untreated patients with RRMS and CIS? – A swiss single center cross-sectional study	17
Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series	17
Predicting long walking capacity from the timed 25-foot walk test in persons with multiple sclerosis – a potential simple aid to assist ambulation scoring?	17
Type of serum collection tube does not impact neurofilament light chain levels	17
Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants	17
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents	17
Aims & Scope & Editorial Board	17
Effects of constraint induced movement therapy in patients with multiple sclerosis: A systematic review	17
New, diagnostic flicker test for optic neuritis shows specific stages following disease onset	17
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial	17
Familial neuromyelitis optica spectrum disorders: Case series and systematic review	16
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran	16
Walking and physical performance in black and white adults with multiple sclerosis controlling for social determinants of health	16
Reliability and Validity of the Arabic Version of Brief International Cognitive Assessment for Multiple Sclerosis in Egyptian Pediatric Multiple Sclerosis Patients	16
RION Vs CRION: The Roadmap	16
Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study	16
Real-world data about the side effects of SARS-CoV-2 vaccinations can be obtained only from representative samples undergoing comprehensive investigations	16
Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease	16
The Use of Ocrelizumab in Pediatric Multiple Sclerosis Patients in the United Arab Emirates: A Retrospective Study	16
The Use of Complementary Medicine for Patients with Multiple Sclerosis in Morocco	16
Healthcare utilisation and perceived healthcare accessibility and quality amongst people living with multiple sclerosis enroled in an online course	16
Physical activity together for MS (PAT-MS): Secondary outcomes of a randomized controlled feasibility trial	16
Role of Type 1 Interferons therapy on Adverse Clinical Outcomes on COVID-19 in Hospitalized Multiple Sclerosis Patients	16
Tobacco Smoke and Sleep Quality Among People with Multiple Sclerosis: A Comparison Study	16

Epidemiological Parameters of Multiple Sclerosis in Chaharmahal- Bakhtiari Province, Iran	16
Neuro rehabilitation effectiveness based on virtual reality and tele rehabilitation in people with multiple sclerosis in Argentina: Reavitelem study	15
Possible evidence of near transfer effects after adaptive working memory training in persons with multiple sclerosis	15
Multiple Sclerosis Patients’ Perception of Traditional and Complementary Medicine	15
Fatigue in Patients with Multiple Sclerosis in an Algeria Cohort	15
Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden	15
Mind wandering in people with Multiple Sclerosis: A psychometric study	15
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis	15
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity	15
Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?	15
The Clinical Course of Multiple Sclerosis Patients in Oran	15
Identification of common susceptibility genes and drug target genes in multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis and its value to guide clinical treatment	15
Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors	15
Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate)	15
Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina	15
Analysis of determinants of treatment change in adult paediatric-onset MS patients	15
Involvement Peripheral Nerve System in Multiple Sclerosis	15
Criterion validity of muscle strain analyses of skeletal muscle function in patients with multiple sclerosis	15
Engagement in volunteering activities by persons with multiple sclerosis in Switzerland	15
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register	15
Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis	15
Risk factors for COVID-19 infection in patients with multiple sclerosis: a nested case–control study	14
A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in Turkey	14
Socioeconomic, health-care access and clinical determinants of disease severity in Multiple Sclerosis in Chile	14
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets	14
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis	14
Electronic pill bottle monitoring versus reminders to promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial	14
The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ): Validation of the Turkish version in patient with multiple sclerosis	14
Two cases of myelin oligodendrocyte glycoprotein antibody-associated disease presenting with Cauda Equina Syndrome without conus myelitis	14
Toxoplasma gondii and multiple sclerosis: a population-based case-control seroprevalence study, Central Anatolia, Turkey	14
Baseline neurofilament levels in cerebrospinal fluid do not correlate with long-term prognosis in multiple sclerosis	14
Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod	14
Is breastfeeding in MS harmful or not? An answer from real-world Czech data	14
Subclinical damage to the contralateral eye in unilateral optic neuritis: A longitudinal study.	14
Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls	14
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study	14
Prevalence of neuromyelitis optica spectrum disorder in Colombia: Analysis of the official Ministry of Health administrative registry	14
Vitamin D3 Improves Behavioral Dysfunction and Promotes Remyelination in Multiple Sclerosis Model Induced by Cuprizone	14
Claims-Based Relapse and Hospitalization Rates in Patients with Multiple Sclerosis Treated with Natalizumab or Ocrelizumab	14
Is computerized screening for processing speed impairment sufficient for identifying MS-related cognitive impairment in a clinical setting?	14
Effects of immersive virtual reality on upper limb function in subjects with multiple sclerosis: A cross-over study	13
Moderate-to-vigorous physical activity is associated with processing speed, but not learning and memory, in cognitively impaired persons with multiple sclerosis	13
A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4	13
The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis	13
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal	13
The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome	13
The relationship between dysphagia, respiratory functions and anthropometry in patients with multiple sclerosis	13
Missed MS or MIMS not prodromal MS: Expanding the diagnostic MS spectrum	13
Patients’ experiences of self-identification, seeking support, and anticipation of potential relapse in multiple sclerosis	13
Diagnosis of multiple sclerosis using optical coherence tomography supported by artificial intelligence	13
Epidemiology of multiple sclerosis in West bank of Palestine	13
Validity of the 30-Second Sit-to-Stand test as a measure of lower extremity function in persons with multiple sclerosis: Preliminary evidence	13
Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication – a retrospective multicentre study	13
Trigeminal neuralgia in multiple sclerosis: Association with demyelination and progression	13
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases	13
Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects	13
A variant of uncertain significance in SDHAF1, the succinate dehydrogenase chaperone protein, in an adult patient with spastic paraparesis and leukoencephalopathy	13
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years	13
Improvements in Quality of Life at 1 Year in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: An Interim Analysis of Clarify-MS	13
A patient with concurrent multiple sclerosis and moyamoya disease	13
Targeting miR-223 enhances myeloid-derived suppressor cell suppressive activities in multiple sclerosis patients	13
Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen	13
Ischemic stroke in neurosarcoidosis: A retrospective cohort analysis	13
Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel	13
Autoimmune encephalitis: A retrospective monocentric experience	13
What telomeres teach us about MS	13
Quantification of normal-appearing white matter damage in early relapse-onset multiple sclerosis through neurite orientation dispersion and density imaging	13
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya	12
Geographic heterogeneity in the association of varicella-zoster virus seropositivity and multiple sclerosis: A systematic review and meta-analysis	12
Real-World Efficacy and Safety Profile of Ocrelizumab in Adult Emirati Multiple Sclerosis Patients: A Retrospective Study from Cleaveland Clinic Abu Dhabi	12
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study	12
Effects of transcranial alternating current stimulation on cognitive function in people with multiple sclerosis: A randomized controlled trial	12
De-Escalation of Anti-CD20 Monoclonal Antibodies to Low-Moderate Efficacy Disease-Modifying Treatments in Patients with Relapse-Remitting Multiple Sclerosis: The Initial Iranian Experience	12
Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis	12
Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis	12
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis	12
Medical Histories and Comorbidities Among Patients with Neuromyelitis Optica Spectrum Disorder, a Comprehensive Study from Iran	12
Is multiple sclerosis a glymphaticopathy?	12
Efficacy and Safety of Rituximab in Moroccan Multiple Sclerosis Patients	12
Impact of automatic tools for detecting new lesions on therapeutic strategies offered to patients with MS by neurologists	12
Is There Any Benefit in Extended-Interval Dosing Regimen of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis? Results from a Systematic Review and Meta-Analysis	12
Oral Status of Patients with MS in a Population of Western and Southwestern Algeria	12
The Adherence and Clinical Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Subcutaneous Interferon Beta-1A: Results from the Main-MS Study	12
An Unusual Presentation of Multiple Sclerosis as Acute Vestibular Syndrome: A Case Report	12
Effects of 6-Month Treatment with Dimethyl Fumarate (DMF) on Treatment Satisfaction and Work Improvement in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (Interim Data Analysis)	12
Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease and Intracranial Hypertension: A Case Report	12
Sexual problems in MS: Sex differences and their impact on quality of life	12
Prevalence and incidence of multiple sclerosis in Isfahan, Iran between 1996 and 2021: A population-based study	12
Safety and Efficacy of Evobrutinib and Tolebrutinib in Relapsing Multiple Sclerosis: A Meta-Analysis of Recent Randomized Control Trials	12
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?	12
Physical Activity in People with Multiple Sclerosis: Which Clinical Characteristics are Important?	12
A Case of Myasthenia Gravis Treated with Ocrelizumab	12
Long-Term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-Up in the CLASSIC-MS Study	12
Is Weight Loss a Presenting Symptom of Multiple Sclerosis	12
Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis	12